These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 15649482)
1. Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat. Chassain C; Bielicki G; Donnat JP; Renou JP; Eschalier A; Durif F Exp Neurol; 2005 Feb; 191(2):276-84. PubMed ID: 15649482 [TBL] [Abstract][Full Text] [Related]
2. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse. Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356 [TBL] [Abstract][Full Text] [Related]
3. Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic resonance spectroscopy. Kanamatsu T; Otsuki T; Tokuno H; Nambu A; Takada M; Okamoto K; Watanabe H; Umeda M; Tsukada Y Brain Res; 2007 Nov; 1181():142-8. PubMed ID: 17919469 [TBL] [Abstract][Full Text] [Related]
4. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Ochi M; Shiozaki S; Kase H Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684 [TBL] [Abstract][Full Text] [Related]
5. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment. Bagga P; Chugani AN; Varadarajan KS; Patel AB J Neurochem; 2013 Nov; 127(3):365-77. PubMed ID: 23957451 [TBL] [Abstract][Full Text] [Related]
6. Role of glial metabolism in diabetic encephalopathy as detected by high resolution 13C NMR. García-Espinosa MA; García-Martín ML; Cerdán S NMR Biomed; 2003; 16(6-7):440-9. PubMed ID: 14679506 [TBL] [Abstract][Full Text] [Related]
7. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. Kickler N; Krack P; Fraix V; Lebas JF; Lamalle L; Durif F; Krainik A; Rémy C; Segebarth C; Pollak P NMR Biomed; 2007 Dec; 20(8):757-62. PubMed ID: 17334978 [TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease. Ochi M; Shiozaki S; Kase H Synapse; 2004 May; 52(2):163-5. PubMed ID: 15034922 [No Abstract] [Full Text] [Related]
9. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735 [TBL] [Abstract][Full Text] [Related]
10. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306 [TBL] [Abstract][Full Text] [Related]
11. Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. Chassain C; Bielicki G; Keller C; Renou JP; Durif F NMR Biomed; 2010 Jul; 23(6):547-53. PubMed ID: 20661872 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. Chung EK; Chen LW; Chan YS; Yung KK J Comp Neurol; 2008 Dec; 511(4):421-37. PubMed ID: 18831527 [TBL] [Abstract][Full Text] [Related]
14. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Yang J; Shen J Neuroscience; 2005; 135(3):927-37. PubMed ID: 16154287 [TBL] [Abstract][Full Text] [Related]
15. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422 [TBL] [Abstract][Full Text] [Related]
16. Metabolism is normal in astrocytes in chronically epileptic rats: a (13)C NMR study of neuronal-glial interactions in a model of temporal lobe epilepsy. Melø TM; Nehlig A; Sonnewald U J Cereb Blood Flow Metab; 2005 Oct; 25(10):1254-64. PubMed ID: 15902201 [TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244 [TBL] [Abstract][Full Text] [Related]
19. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats. Glavan G Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798 [TBL] [Abstract][Full Text] [Related]
20. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata. Yamamoto N; Pierce RC; Soghomonian JJ Brain Res; 2006 Dec; 1123(1):196-200. PubMed ID: 17027936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]